Clinical data

The efficacy of Encala was evaluated in an NIH-sponsored randomized, active placebo-controlled, double-blind study in patients with CF.1

View the educational webinars that Dr. Virginia Stallings has conducted to learn more about the clinical trial and data behind Encala.


Encala resulted in an 8% increase in mean CFA over three months among patients with a mean baseline CFA of 77%

Encala increased weight, height, and BMI for patients with CF who had the greater need

Encala improved absorption and blood levels of essential fatty acids, vitamins A and K, and choline

Encala significantly improves CFA (as shown by mean CFA results1)

Encala improved fatty acids and BMI in subjects with greater need1


Encala clinical trial publications

Unmet needs in patients with CF

General CF and nutrition resources

Scroll to Top